Flu Research Market Analysis and Reports | USA Conference Series

Market Analysis - Flu Research 2018

Importance & Scope:

Flu is an infectious disease caused by the influenza virus. Influenza is a highly contagious disease affecting almost all mammals and birds. Flu occurs globally with an annual attack rate estimated at 5%–10% in adults and 20%–30% in children. Illnesses can result in hospitalization and death mainly among high-risk groups (the very young, elderly or chronically ill). Worldwide, these annual epidemics are estimated to result in about 3 to 5 million cases of severe illness, and about 250 000 to 500 000 deaths.

Experts from various fields like virology, medicine, immunology, microbiology, public health planning, epidemiology, pharmacology and vaccinology all work on the flu virus. 

The infectious diseases therapeutic market in US is estimated to grow at a rate of 3.37% between 2014- 2019. As per the records, 25% of deaths are mainly due to infectious diseases globally. Current market trend shows that North America has the more global market for infectious diseases therapeutics due to increasing incidence of infectious diseases and due to rise in aging population. Followed by North America highest global market is expected in Asia then followed by the Europe in the global infectious diseases therapeutics market.

 

USA

CDC monitors the hospitalizations associated with laboratory-confirmed influenza virus infections Among 9,586 cases with influenza type specified, 8,497 (88.2%) were associated with influenza A virus infection, 1,046 (10.9%) with influenza B virus infection, and 43 (0.4%) were associated with mixed influenza A and influenza B virus infections. Persons aged 18–64 years accounted for 57.4% of reported hospitalizations. The cumulative incidence for all age groups for the period October 1, 2013–April 30, 2014, was 35.6 per 100,000 (Figure 3). The cumulative hospitalization rate (per 100,000 population) by age group for this period was 46.9 (for 0–4 years), 9.5 (5–17 years), 22.0 (18–49 years), 54.3 (50–64 years), and 88.1 (≥65 years).

Fig 1: Hospitalization for Laboratory confirmed influenza

 

Why San Diego ?

San Diego is the eighth-largest city in the United States and second-largest in California with an estimated population of 1,394,928, located on the west coast of the country near to the border with Mexico with attractive beaches and numerous tourist attractions, the city has been given the nickname ‘America's Finest City’. The climate of San Diego, California is categorized as a semi-arid Mediterranean climate. It enjoys mild, sunny weather throughout the year.  The largest sectors of San Diego's economy are tourism, defense/military, international trade, and research/manufacturing, respectively. San Diego is also home to more than 140 contract research organizations (CROs) that provide contract services for pharmaceutical and biotechnology companies. San Diego has hosted several sports events.  

The institutions in and around San Diego consistently rank among the top "National Universities" some of the top ranked universities in San Diego include- University of California, San Diego (UCSD); San Diego State University; University of San Diego, National University, San Diego Mesa College etc., There is also research going on in the areas of banking and finance. Scientists from top universities contribute world class research through the San Diego conferences, workshops and symposiums wherein and professionals from business take part with Great Spirit and add glory to the meetings and workshops organized by Conference Series llc. Another attraction of San Diego is its immediacy to Mexico. Because they share an international border, Tijuana and San Diego are grouped together as an international metropolitan area. San Diego has been called "the birthplace of California”.

The National Galleries of San Diego: Balboa Park, SeaWorld, San Diego Zoo, Gaslamp Quarter, Seaport Village, Old Town State Historic Park, Point Loma and Cabrillo National Monument, San Diego Museum of Art, Midway Aircraft Carrier Museum, Mission Beach, Sunset Cliffs Natural Park, Mission Basilica San Diego de Alcala.

 

Market for Flu and Emerging Infectious Diseases Research:

The market is broken down into vaccines, therapeutics, and diagnostic products. The vaccines segment has the largest share of the market, worth an estimated $3.2 billion in 2009. This segment is expected to grow at a CAGR of 5.6% to reach nearly $4.2 billion in 2014. The therapeutics segment has the second-largest share of the market with $2.1 billion in 2009. But that segment is expected to decrease at a CAGR of -2.4%, falling to $1.9 billion in 2014. As many as 500,000 people die of influenza annually and with the threat of a pandemic, government agencies and disease-prevention organizations are devoted to gaining control of the situation.

The Infectious disease diagnostic (IDD) market is estimated to grow at a CAGR of 7.9% to reach $18,156.2 million by 2019. Traditional diagnostic techniques such as immunodiagnostics and biochemical characterization are the largest segments of the IDD market. However, molecular diagnostic techniques, such as microarrays and isothermal nucleic acid amplification technology (INAAT), will show the fastest growth in the forecast period.

 

Fund Allotment to Flu Research:

The US government awarded five-year contracts for more than $1 billion to five drug manufacturers developing technology for speedier mass production of vaccines in the event of a pandemic from the $3.8 billion pandemic preparedness bill passed in 2005. Currently, flu vaccines are produced in specialized chicken eggs, but that technique does not allow for speedy mass vaccinations." The companies receiving the contracts were:

  • GlaxoSmithKline $274.8 million
  • Medimmune Inc $169.5 million
  • Novartis Vaccines and Diagnostics $220.5 million
  • DynPort Vaccine Company,LLC $41 million
  • Solvay Pharmaceuticals $298.6 million

The US government purchased from Sanofi Pasteur and Chiron Corporation several million doses of vaccine in case of an influenza pandemic due to H5N1 and is conducting clinical trials on them.  ABC News reported that Beginning in late 1997, the human trials have tested 30 different vaccines, all pegged to the H5N1 virus.

 

Fig 2: The focus of activities on research and development of influenza vaccines

 

For H9N2 threat, NIAID contracted with Chiron Corporation to produce investigational batches of an inactivated vaccine, which will be evaluated clinically by NIAID early next year.For H5N1, Aventis-Pasteur and Chiron are both producing investigational lots of inactivated H5N1 vaccine preparations additionally, DHHS has contracted with Aventis to produce up to 2 million doses to be stockpiled for emergency use, if needed, to vaccinate health workers, researchers, and, if indicated, the public in affected areas. Development and evaluation of a combination antiviral regimen against these potential pandemic influenza strains are also now under way.

According to Global Pandemic Influenza Preparedness Markets, their size, trends and drivers, principally for the countries with health expenditures per capita exceeding $2,000. The results of this study found that since outbreaks of bird flu in 2005 and swine flu in 2009, the governments had recognized antiviral pandemic stockpiling as their preferred strategy for disease containment and mitigation. Market Research Media has found that over the past five years, government spending worldwide on Pandemic Influenza Preparedness has more than tripled from $2.2 billion in 2004 to $7 billion in 2009, at a 17% CAGR. Market Research Media forecasts that worldwide government spending on Pandemic Influenza Preparedness will continue to grow, though at more moderate rate of a 5% CAGR, reaching almost $10 billion by 2015.

Fig 3: U.S. government is setting $1 billion to launch development of an H1N1 swine flu vaccine to immunize 20 million people in key positions in health care, national security and emergency services.

 

The HHS announces funding of about $1 billion for clinical studies that will take place over the next few months and for commercial-scale production of two potential vaccine ingredients for the pre-pandemic influenza stockpile.

The following companies will receive funding to produce H1N1 vaccine ingredients:

  • Novartis AG – $289 million,
  • Sanofi Aventis SA – $191 million,
  • GlaxoSmithKline PLC – $181 million,
  • Another $150 million will be directed to produce pilot lots of vaccine and to fund the clinical studies.

 

Conference Highlights

·        Emerging Infectious Diseases

·        Geographic Distribution And Transmission of Emerging infectious disease

·        Factors in the Emergence of Infectious Diseases

·        Host Defenses Against Emerging Infectious Diseases

·        Public Health Measures to Prevent Emerging Infectious Diseases

·        Flu /Influenza Virus

·        Antivirals and Therapeutics for Flu disease

·        Flu Vaccines And Case Reports Of Flu

·        Treatment of Emerging Infectious Diseases

·        Flu/ Influenza Vaccines And Vaccination

·        Antigenic Variation of Flu/ Influenza Virus

·        Flu/ Influenza vaccines : Current And Novel Approach

·        Pathology of Flu/ Influenza virus

·        Symptoms And Treatment Of Flu/Influenza Virus

·        Flu Virus -Advancements in Detection & Differentiation

·         Epidemology and Public Health of Flu/ Influenza

 

Why to attend?

In today's economic climate your business decisions are as crucial as ever. “3rd International Conference on Flu and Emerging Infectious Diseases” allow you to maximize your time and marketing dollars while receiving immediate feedback on your new products and services. 3rd International Conference on Flu and Emerging Infectious Diseases is organizing an outstanding Scientific Exhibition/Program and anticipates the world's leading specialists involved Flu and Infectious Diseases. Your organization will benefit with excellent exposure to the leaders in Flu and Infectious Diseases. Flu and Infectious Diseases -2018 is an exciting opportunity to showcase the new technology, the new products of your company, and/or the service your industry may offer to a broad international audience.

 

Target Audience

Specialists and super specialists, researchers, students, industrial delegates from Academia and Research along with the industrial professionals from biomedical companies and healthcare sectors.

A Unique Opportunity for Advertisers and Sponsors at this International event: https://flu.conferenceseries.com/sponsors.php

 

Societies Associated with Flu Research:

USA

  • International Society for Influenza and other Respiratory Virus Disease
  • American Society for Microbiology
  • American society of virology
  • International Society for Antiviral research
  • American Lung Association
  • Infectious Diseases Society of America

Worldwide

  • European society of virology
  • Vivaldi Biosciences Inc
  • Society for In Vitro Biology
  • Pan American Society for Clinical Virology
  • European Society for Clinical Virology
  • Bill & Melinda Gates Foundation
  • FLURESP
  • Influenza Specialist Group
  • International Society for Infectious Diseases
  • Hellenic Society of Virology

Fig 4: Societies  Associated with Flu Research and Treatment in USA and Worldwide

 

Industries Associated with Flu Research:

California

  • Chiron Corporation
  • Vaxart
  • Novartis
  • Inovio Pharmaceuticals
  • Novarx

USA

  • Flugen
  • Sanofi Pasteur
  • Celldex Therapeutics
  • Emergent BioSolutions
  • Immunomic Therapeutics
  • GlaxoSmithKline

Worldwide

  • Gamma Vaccines
  • bioCSL (CSL)
  • Bavarian Nordic
  • Bharat Biotech
  • Indian Immunologicals
  • Pfizer
  • MedImmune (AstraZeneca)
  • NovaDigm Therapeutics
  • Crucell (Janssen Pharmaceutical)
  • Merck
  • Lonza
  • Pharmajet

Fig 5: Industries Associated with Flu Research and Treatment in California, USA and Worldwide

 

Universities and labs Associated with Flu Research

Universities in California

  • University of California San Francisco
  • University of California Berkeley
  • University of Southern California
  • Stanford University
  • University of California, Los Angeles

Universities in USA

  • University of Illinois at Urbana-Champaign
  • University of Kansas
  • University of Iowa
  • University of Florida
  • Colorado State University
  • John Hopkins University School
  • University of Maryland School of Medicine
  • Saint Louis University School of Medicine
  • University of Oklahoma

Universities Worldwide

  • Griffith University,
  • Monash University in Clayton
  • The University of Melbourne
  • University of Alberta
  • Chinese Academy of Sciences
  • Institut Pasteur
  • University of Milan
  • Cambridge University
  • Imperial College Medical School,
  • Hokkaido University

Fig 6: Universities Associated with Flu Research and Treatment in California, USA and Worldwide

 

Labs  in California

  • Scripps Research Institute
  •  Viral Vector Laboratory

Labs in USA

  • CDC Influenza Division
  • Centers of Excellence for Influenza Research and Surveillance
  • Gresval Labs
  • Southern Research Institute
  • Arthropod-Borne Animal Diseases Research Laboratory

Labs  Worldwide

  • Victorian Infectious Diseases Reference Laboratory
  • MRL Laboratories
  • Virus Reference Laboratories, Inc
  • The Public Health Laboratory
  • Laboratory of Fundamental Virology and Viral Immunology

Fig 7: Virology Department Worldwide

 

Fig 8: Virology Labs Worldwide

Fig 9: Influenza Labs Worldwide

 

Market Value on Flu Research:

The NIH has 5 Centers of Excellence for Influenza Research and Surveillance where groundbreaking research is carried out. The amount of influenza vaccines doses ordered increases by 5% yearly and the NIH spends around $ 312 million dollars on influenza related research yearly. With the increase in the population that falls into the high-risk category the market for flu related products is predicted to rise.

Fig 10: No of conferences held on Flu Research

Products manufactured by the industry related Flu Research and it’s market Value

Aim of the influenza research is to develop influenza countermeasures such as vaccines, therapies and diagnostic tools. At least 12 companies and 17 governments are developing pre-pandemic influenza vaccines in 28 different clinical trials. The Influenza Genome Sequencing Project was initiated in 2004 to create a library of influenza sequences to understand what makes one strain more lethal than another, what genetic determinants most affect immunogenicity, and how the virus evolves over time.

 

Global Influenza Vaccine Market

Influenza vaccines are considered as an optimum source of prevention from diseases caused by flu virus. In 2014, the global market for influenza vaccines has shown tremendous growth backed by certain key prominent factors. Approval of new seasonal influenza vaccines by authorities and significant developments in adjuvant technology are going to impact the market in a positive manner. The global volume sales of influenza vaccine is expected to grow at a CAGR of 5.5% during the forecasted period, i.e., 2014-2020.

The market for seasonal influenza vaccines, sized at US$2.8 billion in 2008–2009 across the seven major markets (United States, Japan, France, Germany, Italy, Spain and UK), has had a strong compound annual growth rate of 12.

Flu is a serious disease that can lead to hospitalization and sometimes even death. Flu vaccination is the best way to prevent people from getting the flu and potentially serious flu-related complications CDC recommends that everyone 6 months and older get a flu vaccination each flu season.

 Fig 11: Global Influenza Market Analysis by Product Segment

 

Global Influenza Vaccine Market

Influenza vaccines are considered as an optimum source of prevention from diseases caused by flu virus. In 2014, the global market for influenza vaccines has shown tremendous growth backed by certain key prominent factors. Approval of new seasonal influenza vaccines by authorities and significant developments in adjuvant technology are going to impact the market in a positive manner. The global volume sales of influenza vaccine is expected to grow at a CAGR of 5.5% during the forecasted period, i.e., 2014-2020.

The market for seasonal influenza vaccines, sized at US$2.8 billion in 2008–2009 across the seven major markets (United States, Japan, France, Germany, Italy, Spain and UK), has had a strong compound annual growth rate of 12.

Flu is a serious disease that can lead to hospitalization and sometimes even death. Flu vaccination is the best way to prevent people from getting the flu and potentially serious flu-related complications CDC recommends that everyone 6 months and older get a flu vaccination each flu season.

Fig 12: Early Season and End of season flu vaccination coverage in USA

 

The growth potential for players in the vaccine market is vast and growing larger every day. According to GBI Research, the global vaccine market is expected to be valued at $52 billion by 2016. Experts say this flu season has been the worst in a decade. There were 14 flu related deaths in San Diego County alone, which makes the total number of deaths due to influenza staggering. Predictably, seasonable influenza vaccine demand stands at142 million doses this year. This number is expected to increase to a staggering 158 million in 2022. India, China, Japan and the EU's major economies could see exponential growth in the demand for flu vaccines over the next decade. Vaccine manufacturers could profit immensely if they develop a vaccine that can fight off most common strains of influenza.

Fig 13: Market potential for vaccine production

 

Global Influenza Antiviral Drug Market

The current marketplace for influenza therapeutics is dominated by two drugs (Tamiflu (Roche) and Relenza (GSK)) with combined annual sales in 2009 over $4 Billion1 ). Tamiflu is taken orally while Relenza must be inhaled - requiring a dedicated inhaler. However, both drugs target the influenza neuraminidase and viral resistance (to Tamiflu in particular) has been demonstrated and is a growing concern. Tamiflu (oseltamivir phosphate), Relenza (zanamivir) and Rapivab (peramivir) are the three FDA-approved influenza antiviral drugs recommended by CDC for use against recently circulating influenza viruses. Older drugs, amantadine and rimantadine, are approved for treatment and prevention of influenza A. But many strains of influenza, including the 2009 H1N1 influenza, are now resistant to these two drugs. CDC has not recommended the use of these two drugs for recently circulating influenza viruses, although recommendations could change if there were future re-emergence of specific virus strains with susceptibility patterns favoring such use.

Fig 14: Antiviral Drug for Influenza Treatment

 

Reference:

  1. http://www.cdc.gov/flu/weekly/fluactivitysurv.htm
  2. http://www.cdc.gov/flu/international/program/index.htm
  3. http://www.cdc.gov/flu/weekly/fluactivitysurv.htm
  4. http://www.niaid.nih.gov/topics/flu/Pages/default.aspx
  5. http://www.niaid.nih.gov/topics/flu/Pages/default.aspx
  6. http://www.niaid.nih.gov/topics/flu/Pages/default.aspx
  7. http://www.idsociety.org/Research_and_Funding_Opportunities/
  8. http://www.niaid.nih.gov/news/newsreleases/2014/Pages/CEIRSnetwork.aspx
  9. https://en.wikipedia.org/wiki/Influenza_research
  10. http://www.fludb.org/brc/home.spg?decorator=influenza
  11. https://www.influenzareagentresource.org/
  12. https://www.influenzareagentresource.org/About/IRR.aspx
  13. https://www.beiresources.org/Organism/12/Influenza.aspx
  14. http://www.atcc.org/en/About/Grants_and_Contracts/Influenza_Reagent_Resource.aspx
  15. http://www.influenzavir.com/cms/

 

Your rejoinder is our inspiration; keeping this motto in mind and being witnessed the triumph of Flu 2016, ConferenceSeries Ltd is delighted to announce the next event

Conference Series invites all the participants from all over the world to attend 3rd International Conference on Flu & Emerging Infectious Diseases during September 17-18, 2018 at San Diego, USA.

The field of Flu & Emerging Infectious Diseases is growing rapidly and its development is making tremendous impacts in medical sciences and pharmaceuticals. The importance and significance can be gauged by the fact that it has made huge advancements over the course of time and is continuing to influence various sectors.

World Flu & Emerging Infectious Diseases 2018

 Opportunity to attend the presentations delivered by eminent scientists from all over the world. Selected contributions will be published in following Conference Series Journals             

·         Virology & Mycology

·         Virology & Antiviral Research

·         Journal of Vaccines & Vaccination

Participation in sessions on specific topics on which the conference is expected to achieve progress

Global networking: In transferring and exchanging Ideas

Conference brings together Scientific Researchers, Virologists, Immunologists, Microbiologists, Pathologists, Infectious Diseases Specialists, Health Care Professionals and Physicians